{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:48:05Z","timestamp":1792162085978,"version":"4.4.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>To assess efficacy of radioimmunotherapy (<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content>) in follicular lymphoma, data from 281 patients collected in the <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> Network, with a median follow\u2010up of 8\u00b72\u00a0years after <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> were analysed. <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> was given at first line in 18\u00b75% and at relapse in 81\u00b75%. Following first line therapy, 76\u00b79% achieved complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>), 9\u00b76% partial remission (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>), 1\u00b79% stable disease (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) and 1\u00b79% had progressive disease (<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>); response was not documented in 9\u00b77%. At relapse, the rate of <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> was 48\u00b75% and that of <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> was 16\u00b76%, <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 2\u00b76% and <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content> 10\u00b75%; response was not documented in 21\u00b78%. After median follow\u2010up of 8\u00b72\u00a0years, median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) for all was 2\u00b754\u00a0years, median overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) was not reached. Median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (both not reached) were significantly better in first line, compared to <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> at relapse (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>, 2\u00b711\u00a0years; <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>, 10\u00b78\u00a0years; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b70037 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b70021, respectively). Overall 8\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 33\u00b79%, 53\u00b76% for first line and 29\u00b76% for relapsed individuals. Overall 8\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 58\u00b78%, 78\u00b71% for first line and 54\u00b75% for relapsed patients. Thirty\u2010five patients (12\u00b75%) developed secondary malignancy and 16 patients (5\u00b77%) experienced transformation into aggressive lymphoma. <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> is a safe and effective treatment option for follicular lymphoma, both at front line and relapse with an 8\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> of 53\u00b76% and 29\u00b76%, respectively.<\/jats:p>","DOI":"10.1111\/bjh.15712","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T02:26:27Z","timestamp":1543976787000},"page":"949-956","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radioimmunotherapy (<scp>RIT<\/scp>) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8\u2010year follow\u2010up data of 281 patients from the international <scp>RIT<\/scp>\u2010registry"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-3274","authenticated-orcid":false,"given":"Karin","family":"Hohloch","sequence":"first","affiliation":[{"name":"Kantonsspital Graub\u00fcnden Department of Haematology and Oncology Chur Switzerland"},{"name":"Department of Haematology and Oncology Georg August University Goettingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Windemuth\u2010Kieselbach","sequence":"additional","affiliation":[{"name":"Alcedis GmbH Independent CRO Giessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kolz","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology Georg August University Goettingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia e Oncologia Medica Universit\u00e0 di Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cacchione","sequence":"additional","affiliation":[{"name":"CEMIC Centro de Educaci\u00f3n, M\u00e9dica e Investigaciones Cl\u00ednical \u201cNorberto Quirno\u201d Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woijciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Haematology Jagiellonian University Cracow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bischof Delaloye","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia e Oncologia Medica Universit\u00e0 di Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology Vivantes Klinikum Am Urban Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.684"},{"key":"e_1_2_10_4_1","volume-title":"Part 11 of Title 21 of the Code of Federal Regulations; Electronic Records; Electronic Signatures (21 CFR Part 11)","author":"FDA","year":"1997"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12695"},{"key":"e_1_2_10_11_1","volume-title":"GAMP\u00ae Good Practice Guide: Validation and Compliance of Computerized GCP Systems and Data","author":"International Society for Pharmaceutical Engineering","year":"2017"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood.V122.21.369.369","article-title":"A randomized phase II study comparing consolidation with a single dose of 90y ibritumomab tiuxetan (Zevalin\u00ae) (Z) vs. maintenance with rituximab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R\u2010CHOP. Preliminary results at 36\u00a0months from randomization","volume":"122","author":"Lopez\u2010Guillermo A.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_10_17_1","first-page":"6701","article-title":"Radiotherapy for stage I\/II follicular lymphoma (FL): is it time for a re\u2010appraisal?","volume":"34","author":"Mondello P.","year":"2014","journal-title":"Anticancer Research"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0012-3"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.790544"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486788"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T16:30:32Z","timestamp":1694709032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bjh.15712"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15712","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"2018-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}